

# Discovery of lead compounds for the development of triple negative breast cancer treatments through HDAC6/8 dual inhibition

Sookmyung Women's University



| ONCOLOGY                 | Lead  |
|--------------------------|---|
| Product Type             | Chemical Product  |
| Indication               | 1st indication: Triple negative breast cancer (TNBC)  |
| Target                   | Histone deacetylase 6/8 (HDAC 6/8)  |
| MoA(Mechanism of Action) | Selectively HDAC6 & HDAC8 dual inhibition → Anti-proliferation, inhibition of metastasis, and immune modulation → Effective therapy for TNBC  |
| Competitiveness          | First-in-class <ul style="list-style-type: none"> <li>• No HDAC-targeted TNBC therapy</li> <li>• Can be used as a first-line treatment with reduced side effects by replacing standard treatments</li> <li>• Combination therapy of a HDAC inhibitor and an immuno-ONCOLOGY agent can increase the sensitivity of the immuno-ONCOLOGY agent, thereby exhibiting a synergistic anticancer effect.</li> </ul> |
| Development Stage        | Lead  |
| Route of Administration  |   |